- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000917
Setting up a Blood Bank for Gene Therapy in HIV-Infected Infants
Establishment of a Cord Blood Bank for Gene Therapy in HIV-Infected Infants
The purpose of this study is to set up a blood bank for infants who have HIV-positive mothers. This blood may be used in the future to treat the child if he/she turns out to be HIV-positive.
Blood from the umbilical cord contains a certain kind of cell called a stem cell. Stem cells eventually turn into one of the many types of blood cells. If HIV infection can be prevented in these stem cells, then, when these stem cells are injected back into the infant, the new cells that develop will also be protected from HIV. This study will provide the blood needed to test whether this type of gene therapy is safe and effective.
Study Overview
Status
Conditions
Detailed Description
Gene therapy may provide a new therapeutic approach to pediatric AIDS. Putting an HIV-resistant gene into umbilical cord blood stem cells and transplanting the cells back into the patient could lead to the production of cells that resist HIV infection. If a patient's cells could be engineered to be resistant to supporting the growth of HIV-1, the cells may have improved survival in the presence of HIV-1. To date, an umbilical cord blood bank for HIV-positive deliveries has not been established in the United States. This protocol establishes a repository of banked umbilical cord blood as a first step toward the potential application of gene therapy for the treatment of HIV-infected infants.
HIV-infected mothers have about 20 ml of blood drawn to test for infectious diseases (e.g., hepatitis). At time of delivery maternal HIV viral load is measured. After delivery, about 60 ml of blood is collected from the umbilical cord; this blood is labeled and transferred to the umbilical cord blood bank for possible use in future gene therapy studies on the infant. At birth, infant HIV status and general health are assessed. If the infant is found to be HIV-infected, the mother may be approached about the infant's participation in a future gene therapy study. If the infant is not HIV-infected, the cord blood is stored for up to four years and is then released to the mother, or, with her consent, to the research community.
Study Type
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 920930672
- UCSD Med Ctr / Pediatrics / Clinical Sciences
-
Long Beach, California, United States, 90801
- Long Beach Memorial (Pediatric)
-
Los Angeles, California, United States, 90033
- Los Angeles County - USC Med Ctr
-
Los Angeles, California, United States, 900481804
- Cedars Sinai / UCLA Med Ctr
-
Los Angeles, California, United States, 905022004
- Harbor - UCLA Med Ctr / UCLA School of Medicine
-
Los Angeles, California, United States, 900951752
- UCLA Med Ctr / Pediatric
-
San Francisco, California, United States, 94110
- San Francisco Gen Hosp
-
San Francisco, California, United States, 941430105
- UCSF / Moffitt Hosp - Pediatric
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
You may be eligible for this study if you:
- Are HIV-positive.
Exclusion Criteria
Your child will not be eligible for this study if he/she:
- Is not expected to live more than 6 months.
- Weighs less than 3.3 pounds.
Study Plan
How is the study designed?
Collaborators and Investigators
Investigators
- Study Chair: Savita Pahwa
- Study Chair: Howard Rosenblatt
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACTG 385
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed